Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

AW. Langerak, M. Ritgen, V. Goede, S. Robrecht, J. Bahlo, K. Fischer, M. Steurer, M. Trněný, SP. Mulligan, UJM. Mey, K. Trunzer, G. Fingerle-Rowson, K. Humphrey, S. Stilgenbauer, S. Böttcher, M. Brüggemann, M. Hallek, M. Kneba, JJM. van Dongen,

. 2019 ; 133 (5) : 494-497. [pub] 20181119

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, dopisy, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19045128

Charles University Hospital Prague Czech Republic

Department of Hematology University of Schleswig Holstein Kiel Germany

Department of Hematology University of Schleswig Holstein Kiel Germany Clinic 3 Hematology Oncology and Palliative Medicine University of Rostock Rostock Germany

Department of Immunology Laboratory for Medical Immunology Erasmus University Medical Center Rotterdam The Netherlands

Department of Immunology Laboratory for Medical Immunology Erasmus University Medical Center Rotterdam The Netherlands Department of Immunohematology and Blood Transfusion Leiden University Medical Center Leiden The Netherlands

Division of Hematology and Oncology Medical University of Innsbruck Innsbruck Austria

German CLL Study Group Department 1 of Internal Medicine and Center of Integrated Oncology Cologne Bonn University Hospital of Cologne Cologne Germany

German CLL Study Group Department 1 of Internal Medicine and Center of Integrated Oncology Cologne Bonn University Hospital of Cologne Cologne Germany Cologne Center of Excellence for Cellular Stress Response and Aging Related Diseases University of Cologne Cologne Germany

Internal Medicine 3 University of Ulm Ulm Germany

Kantonsspital Graubünden Chur Switzerland

Oncogeriatric Unit Department of Geriatric Medicine St Marien Hospital Cologne Germany German CLL Study Group Department 1 of Internal Medicine and Center of Integrated Oncology Cologne Bonn University Hospital of Cologne Cologne Germany

Pharma Development Oncology F Hoffmann La Roche Ltd Basel Switzerland

Pharma Development Oncology Roche Products Ltd Welwyn United Kingdom

Royal North Shore Hospital University of Sydney Sydney Australia

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045128
003      
CZ-PrNML
005      
20250108120507.0
007      
ta
008      
200109s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood-2018-03-839688 $2 doi
035    __
$a (PubMed)30455380
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Langerak, A. W., $u Department of Immunology, Laboratory for Medical Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands. $d 1967- $7 xx0310084
245    10
$a Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab / $c AW. Langerak, M. Ritgen, V. Goede, S. Robrecht, J. Bahlo, K. Fischer, M. Steurer, M. Trněný, SP. Mulligan, UJM. Mey, K. Trunzer, G. Fingerle-Rowson, K. Humphrey, S. Stilgenbauer, S. Böttcher, M. Brüggemann, M. Hallek, M. Kneba, JJM. van Dongen,
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a chlorambucil $x terapeutické užití $7 D002699
650    _2
$a komorbidita $7 D015897
650    _2
$a lidé $7 D006801
650    _2
$a chronická lymfatická leukemie $x diagnóza $x farmakoterapie $x epidemiologie $7 D015451
650    _2
$a lidé středního věku $7 D008875
650    _2
$a reziduální nádor $x diagnóza $x farmakoterapie $x epidemiologie $7 D018365
650    _2
$a prognóza $7 D011379
650    _2
$a prospektivní studie $7 D011446
650    _2
$a rituximab $x terapeutické užití $7 D000069283
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a dopisy $7 D016422
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ritgen, Matthias $u Department of Hematology, University of Schleswig-Holstein, Kiel, Germany.
700    1_
$a Goede, Valentin $u Oncogeriatric Unit, Department of Geriatric Medicine, St. Marien Hospital, Cologne, Germany. German CLL Study Group, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany.
700    1_
$a Robrecht, Sandra $u German CLL Study Group, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany.
700    1_
$a Bahlo, Jasmin $u German CLL Study Group, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany.
700    1_
$a Fischer, Kirsten $u German CLL Study Group, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany.
700    1_
$a Steurer, Michael $u Division of Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.
700    1_
$a Trněný, Marek $u Charles University Hospital, Prague, Czech Republic.
700    1_
$a Mulligan, Stephen P $u Royal North Shore Hospital, University of Sydney, Sydney, Australia.
700    1_
$a Mey, Ulrich J M $u Kantonsspital Graubünden, Chur, Switzerland.
700    1_
$a Trunzer, Kerstin $u Pharma Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
700    1_
$a Fingerle-Rowson, Günter $u Pharma Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
700    1_
$a Humphrey, Kathryn $u Pharma Development Oncology, Roche Products Ltd, Welwyn, United Kingdom.
700    1_
$a Stilgenbauer, Stephan $u Internal Medicine III, University of Ulm, Ulm, Germany.
700    1_
$a Böttcher, Sebastian, $d 1971- $u Department of Hematology, University of Schleswig-Holstein, Kiel, Germany. Clinic III, Hematology, Oncology and Palliative Medicine, University of Rostock, Rostock, Germany. $7 xx0327357
700    1_
$a Brüggemann, Monika $u Department of Hematology, University of Schleswig-Holstein, Kiel, Germany.
700    1_
$a Hallek, Michael $u German CLL Study Group, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany. Cologne Center of Excellence for Cellular Stress Response and Aging Related Diseases, University of Cologne, Cologne, Germany; and.
700    1_
$a Kneba, Michael $u Department of Hematology, University of Schleswig-Holstein, Kiel, Germany.
700    1_
$a van Dongen, Jacques J M $u Department of Immunology, Laboratory for Medical Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands. Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 133, č. 5 (2019), s. 494-497
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30455380 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20250108120502 $b ABA008
999    __
$a ok $b bmc $g 1483397 $s 1083801
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 133 $c 5 $d 494-497 $e 20181119 $i 1528-0020 $m Blood $n Blood $x MED00000807
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace